Why is Balaxi Pharma falling/rising?

As of 26-Aug, Balaxi Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 45.66, reflecting a decrease of 1.21 or 2.58%. The stock has underperformed its sector today by 0.57%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has dropped by 4.16%, and it has seen a significant decline of 36.86% year-to-date. Despite a strong long-term fundamental strength indicated by an average Return on Equity (ROE) of 30.97% and a fair valuation compared to peers, the stock's performance has been negatively impacted by a 49.8% drop in profits over the past year, alongside a substantial decline in institutional investor participation, which has decreased by 7.16%.
In the broader market context, Balaxi Pharmaceuticals has consistently underperformed against the benchmark, with a 57.35% decline over the past year compared to a 1.19% drop in the Sensex. This consistent underperformance over the last three years, coupled with negative financial results reported in June, has contributed to a lack of confidence among investors. The stock's liquidity remains adequate for trading, but the falling participation from institutional investors suggests a cautious outlook, which may further pressure the stock's price in the near term.